Table 1.
Pharmacokinetic parameters of selected antipsychotics101
| Drug | Bioavailability (%) | Half-life (h) | Major metabolic pathway | Active metabolites | Dosage forms |
|---|---|---|---|---|---|
| Aripiprazole | 87 | 48–68 Dehydroaripiprazole: 75–46 |
CYP3A4, CYP2D6 | Y | T, O, L |
| Clozapine | 12–81 | 11–105 | CYP1A2, CYP3A4, CYP2C19 | Y | T, O |
| Olanzapine | 80 | 20–70 | CYP1A2, CYP3A4, FMO3 | Y | T, I, O |
| Paliperidone ER | 28 | 23 | Renal unchanged (59%) Multiple pathway |
N | ER |
| Quetiapine | 5–13 | 7 | CYP3A4 | Y | T |
| Risperidone | 68 | 3–24 | CYP2D6 | Y | T, O, L |
| Risperidone Consta® | 3–6 days | CYP2D6 | Y | LAI | |
| Ziprasidone | 59 | 4–10 | Aldehyde oxidase, CYP3A4 | N | C, I |
Abbreviations: C, capsules; ER, extended release; I, injection; L, liquid solution, elixir or suspension; LAI, long-acting injectable; O, orally disintegrating tablets; T, tablet.